I treat AI vendor disclosures as a starting point - not permission to deploy. Before a healthcare delivery organization (HDO) approves a tool, I check whether its claims fit your patients, data, and care workflow.
I focus on 5 areas:
- Model limits: Where the tool fails, how it was tested, and when staff should question its output.
- Training data: Where the data came from, whom it represents, and what use rights apply.
- Human review: Who checks outputs, can reject recommendations, and handles escalation.
- Patient impact: Risks to diagnosis, treatment, privacy, and access to care.
- Issue tracking: How vendors report incidents, monitor performance, and handle changes or rollback.
My rule: Assign an owner, a deadline, and a response threshold to each unresolved risk. I follow best practices for managing third-party AI risk before purchase, deployment, major changes, and scheduled re-review. For critical incidents, this framework calls for immediate escalation and written notice within 4 hours.
<u>A completed checklist is not approval.</u> I use the findings to record a clear decision, set contract terms, and plan monitoring. Risk-management software can help track that work; it cannot establish clinical safety or replace HDO accountability.
HDO AI Vendor Disclosure Review Framework
Checklist: Model Limits and Training Data
Use this checklist to confirm that the vendor’s model limits, data sources, and rights fit the HDO’s patients, workflow, and risk tolerance.
Check Performance and Failure Modes
Require metrics for the specific model version, intended use, and decision threshold. These should include sensitivity, specificity, positive predictive value, negative predictive value, calibration, confidence intervals, sample size, prevalence, and cohort description.
Require external validation using data from a different organization, patient population, and workflow. Note whether testing was retrospective, prospective, silent, or live. Include a clinical or operational baseline comparison, plus subgroup results with sample sizes, missing-data rates, and confidence intervals. Retrospective results alone may overstate effectiveness because of selection bias and data leakage.[7][8] Compare the tested patients and workflow with the HDO’s own, rather than relying on headline accuracy.
Test inputs that are missing, delayed, conflicting, manipulated, out of range, low quality, or out of distribution. Require documented uncertainty, abstention rules, and escalation triggers. A confidence score alone is not enough. Specify when verification is required.
For each limitation, record the harm, likelihood, severity, detection method, mitigation, owner, escalation trigger, and enterprise risk. Identify where performance breaks down, including rare diseases, pediatric patients, older adults, patients with limited English proficiency, unusual clinical presentations, and changes in equipment or coding practices. Determine which changes in patient mix, equipment, coding, or data completeness could reduce performance and trigger reassessment.[9]
Review Data Sources and Use Rights
Require a data inventory covering source organizations, data types, collection periods, geography, care settings, patient demographics, disease prevalence, inclusion and exclusion criteria, device or software versions, labeling procedures, preprocessing, missingness handling, and data-quality controls.
Check labeler qualifications, clinical definitions, disagreement resolution, known bias, and error analysis by site and subgroup. Verify patient-level dataset separation where appropriate, deduplication, and safeguards against temporal leakage, duplicate records, or post-outcome information. Compare these details with local patients and workflow to identify dataset shift, including differences in disease prevalence.[10][11]
Confirm explicit rights for each data source and for using HDO data in training, fine-tuning, validation, benchmarking, or product improvement. Also confirm terms for PHI access, encryption, storage locations, retention, deletion - including backups - subcontractor access, and applicable business associate obligations.
Request a data lineage statement that traces sources, transformations, custodians, and permitted uses. Require enough provenance and rights information to assess representativeness, generalizability, and legal use. Put sensitive source details in a restricted-access appendix.
Score each disclosure against these requirements before assigning approval status.
Rate Disclosure Quality
Use sufficient for current, verifiable evidence that fits the HDO; partial when material detail or local validation is missing; and unacceptable for unsupported claims, material omissions, or withheld provenance or data-use terms.
Every “not applicable” response must identify the criterion, explain the reason, name the responsible authority, and state the evidence considered.
| Disclosure item | Vendor response | Supporting evidence | HDO relevance | Identified risk | Required remediation | Approval status |
|---|---|---|---|---|---|---|
| Intended-use performance | Metrics, cohort details, and external validation provided | Validation report or peer-reviewed study | Matches HDO patients and workflow | Residual performance uncertainty | Confirm local validation and monitoring thresholds | Pending local checks |
| Failure modes | Failure conditions, abstention, verification, and escalation documented | Hazard analysis, test cases, user guide | Defines when clinicians must not rely on output | Missed or unsafe recommendations | Close gaps in examples or thresholds; add workflow controls and training | Conditional on HDO acceptance of controls |
| Training-data provenance | Sources, dates, populations, labeling, separation controls, and rights documented | Data lineage statement | Supports representativeness and legal-use assessment | Dataset shift, bias, or reuse without permission | Obtain missing provenance or contract limits | Hold approval until material gaps are resolved |
| PHI handling | Retention, deletion, access, storage, subcontractor, and training-use terms provided | Business associate agreement and security documentation | Defines privacy and compliance exposure | Disclosure or secondary use without permission | Amend contract and verify technical controls | Hold approval until resolved |
sbb-itb-535baee
Checklist: Human Review and Patient Impact
Connect vendor disclosures to local reviewers, escalation paths, and patient-safety thresholds.
Assign Review Duties and Clinical Accountability
Once model limits and data rights are clear, define who reviews outputs and how local staff should act on them.
Require human review before action for outputs that affect diagnosis, triage, medication, treatment, discharge, or care access. Set reviewer credentials, response deadlines, evidence requirements, documentation rules, and prohibited actions. Give reviewers enough context to judge each recommendation independently.
Require role-based training and competency checks to test whether staff can spot unsafe recommendations. Reviewers must be able to reject outputs without penalty and have a clear path to a second reviewer or specialist. To reduce automation bias, show relevant source information and avoid default acceptance.
Track review completion, disagreement, overrides, and review time. Investigate unusually low disagreement rather than treating it as a sign of quality. Check periodically that staff follow the procedures.
Use the matrix below to assign ownership. Replace role labels with named owners before approval. For each activity, record required evidence, escalation triggers, notification deadlines, and retention terms.
Audit records should include the model version, input reference, output, reviewer, decision, override reason, and resulting action. Require export access and a tested manual fallback for outages or unreliable outputs. Treat missing output as no result, never as a negative result.
| Activity | Vendor duty | HDO duty and accountable role |
|---|---|---|
| Validation and workflow approval | Supply testing evidence and implementation requirements | Clinical lead owns local acceptance and deployment approval |
| Training and output review | Provide role-based materials and technical support | Clinical operations lead verifies competence and override authority |
| Incident response | Investigate defects and support remediation | Patient-safety lead coordinates response; privacy/security team assesses reporting duties |
| Model changes and downtime | Provide change notices and rollback support | Application owner coordinates review before production changes and fallback testing |
| Patient communications and corrections | Support notices, complaints, and corrections | Patient-support lead coordinates notices and requests with clinical and privacy teams |
Assess Patient Safety and Equity Risks
After assigning review duties, test the vendor’s claims against patient harm and access risks.
Require vendors to disclose intended patient benefits and foreseeable harms involving diagnosis, treatment, privacy, communication, and access. Verify that these disclosures apply to the local workflow.
Assess subgroup differences in errors and time to intervention - not just aggregate accuracy. Require sample sizes and uncertainty estimates where feasible, and identify groups with insufficient evidence.
For patient-facing tools, check supported languages, interpreter needs, assistive technology compatibility, and reading level. Determine which patient notices apply. Provide an accessible way to request human review or correction, with a response deadline and escalation contact.
Build a patient harm register using the categories below, rather than assumed scores. Score likelihood and severity from 1–5, then multiply them for an initial score. Review rare catastrophic harms separately.
Before approval, set numeric monitoring thresholds, response deadlines, and pause conditions. Reassess scores and thresholds through repeated measurement, not a one-time review.
| Harm scenario | Affected groups | Vendor disclosure and local verification | Likelihood and severity | Required controls | Monitoring and threshold to define | Owner, residual-risk decision, and approval status |
|---|---|---|---|---|---|---|
| Missed or delayed diagnosis | Patients with atypical presentations or language barriers | Vendor discloses false negatives and subgroup limitations; HDO verifies local diagnostic performance and delays | Rate each using workflow evidence | Clinician review; independent assessment of symptoms | False-negative rate and time to intervention; set investigation and pause thresholds | Clinical safety lead records residual risk, acceptance decision, and approval status |
| Unsafe medication recommendation | Patients receiving medication-related outputs | Vendor discloses medication errors and limitations; HDO verifies recommendations against local medication-safety requirements | Rate each using medication-safety evidence | Qualified clinician approval before action | Clinically significant recommendation errors; set escalation threshold | Medication-safety lead records residual risk, acceptance decision, and approval status |
| Delayed or inaccessible care | Patients with disabilities, limited English proficiency, or low health literacy | Vendor discloses language, accessibility, and usability limitations; HDO verifies local access and usability | Rate each using access and usability evidence | Accessible communications, interpreter support, and human review | Access delays, complaints, and subgroup gaps; set corrective-action threshold | Access lead records residual risk, acceptance decision, and approval status |
Checklist: Issue Tracking and Lifecycle Reporting
Once local review duties are set, define how defects, harms, and model changes will be logged, escalated, and closed.
Set Incident Logging and Notification Terms
Require the vendor to spell out reporting terms in a contractual AI incident, change, and lifecycle reporting schedule. Use a shared, version-controlled register to track defects, near misses, harmful or materially wrong outputs, bias findings, privacy or security incidents, outages, complaints, root-cause analyses, and corrective actions. Include requirements for preserving evidence and supporting investigations. NIST recommends tracking incidents and system changes throughout deployment.[14]
| Required register fields | What to record |
|---|---|
| Identification and exposure | Incident ID; product, model, version, configuration, integration, workflow, and clinical setting; affected or potentially affected population, including relevant demographic or clinical subgroups |
| Severity and timing | Severity; likelihood; actual or potential patient harm; whether care was delayed or altered; discovery date; HDO notification date; regulatory-reporting status |
| Containment and ownership | Containment actions; vendor and HDO owners; escalation contacts; residual risk |
| Investigation and closure | Evidence; sample outputs; logs; relevant data lineage; root cause; corrective and preventive actions; verification results and date; resolution date; closure rationale |
Set severity-based contractual deadlines:
- Critical: Immediate verbal escalation and written notice within 4 hours.
- High: Notice within 1 business day.
- Moderate: Notice within 3 business days.
- Low: Monthly or quarterly reporting.
Define when the clock starts, who must be contacted, when interim updates are due, and the final-report format. Initial notice must not wait for a completed investigation. Contractual deadlines do not replace applicable federal or state reporting duties.
Use these records to guide monitoring, change review, and rollback decisions.
Check Monitoring and Model Change Controls
Require reports that compare deployed performance with the approved baseline. Reports must disclose drift, subgroup gaps, missing-data patterns, integration failures, and unresolved issues. Give each metric a threshold, review frequency, owner, and escalation action.
Review high-impact clinical tools quarterly and lower-risk tools at least annually. Reassess whenever the model, data, workflow, integration, hosting, output type, review process, or regulatory status changes. This includes deployment for a new intended use or patient population. NIST treats post-deployment monitoring as a continuing part of risk management.[6][9]
Require advance notice and release notes for material changes. Include current and proposed version numbers; the reason for the change; affected workflows, populations, and integrations; validation and subgroup-performance results; known limitations and new failure modes; security, privacy, interoperability, and usability testing; the implementation date; deployment method; and rollback procedure.[13][15]
Reserve HDO approval before production deployment. Emergency patches still require notice and documented review. Require access to logs and testing records, along with tested rollback and safe decommissioning procedures. Do not assume an earlier version is safe to restore.[6][9]
Run a tabletop drill before go-live and after any material change or deployment in a new population, integration, or clinical workflow. Test:
- Escalation contacts, severity classification, and HDO stop-use authority.
- Patient review and collection of evidence about affected versions, populations, outputs, and audit logs.
- Vendor root-cause analysis and interim findings.
- Clinician instructions and safe fallback.
- Assessment of patient and regulatory notification needs.
- Validation, monitoring, and HDO approval to restart.
- Decision records, evidence, dissenting views, and closure rationale.
Document gaps, owners, deadlines, and required contract or workflow changes in an after-action report.
Conclusion: Record Decisions and Maintain Oversight
Complete the HDO Approval Record
Once disclosure checks are complete, turn the findings into a formal decision record. A completed disclosure review is evidence - not approval. Document the vendor, product version, approved intended use, prohibited uses, patient population, deployment scope, and decision date, incorporating common healthcare third-party risk assessment questions into the record. Link verified evidence for all five disclosure areas: model limits, training data, human review, patient impact, and issue tracking. Include each source’s version, review date, and verification limits.
Mark the decision as approved, approved with conditions, deferred, or rejected. Every unresolved risk needs an explicit acceptance decision. Silence doesn't count. For conditional approval, specify owners, deadlines, required evidence, an expiration date, and suspension criteria. Missing validation should lead to deferred or conditional approval - not an open-ended exception.
Name the clinical, privacy, security, legal, compliance, and procurement owners. Document tested workflow controls and contractual obligations for data use, PHI, security, reporting, and audits. Assign monitoring owners, and tie approval to patient-safety thresholds, reassessment triggers, and the next review date.
Coordinate Risk Reviews With Censinet RiskOps
Use the approval record to move open issues, owners, and deadlines into a shared risk register. Censinet RiskOps™ can support centralized third-party risk assessments, collaborative risk management, evidence collection, remediation tracking, and stakeholder routing.[16][17]
Set up human review and approval so clinical, privacy, security, legal, and compliance stakeholders review findings within their areas of responsibility. Keep clinical validation separate from technical and security assessments. Risk-management software supports oversight; it does not establish clinical safety or replace HDO accountability.[12]
FAQs
What if an AI vendor withholds proprietary data?
Treat withheld proprietary data as a serious transparency gap [1]. Pause procurement or approval immediately until the vendor supplies the proof you need [1][2].
If the vendor can’t verify its security posture, show that its model can be audited, or provide a complete AI Bill of Materials (AIBOM) and model card, reject the vendor or limit the tool to a small pilot [1][2]. For fine-tuning data, decide what level of detail the summary must include to support your risk assessment [3].
How much local validation is enough before deployment?
Performance in your setting may differ from vendor demonstrations [1]. Before deployment, check expected performance using representative datasets and cross-validation against human expert judgment [2].
For high-risk or critical tools, run a limited production pilot, such as shadow mode or a staged rollout, to assess performance in actual use. Record all verification results, deviations, and corrective actions in the system’s lifecycle documentation so it’s ready for an audit [2].
How do we set AI stop-use thresholds?
Build a risk-based approach into your governance framework. Define how much risk your organization will accept, including patient safety thresholds and the conditions AI must meet before deployment in life-critical systems [1][2][3].
During procurement, include performance and safety metrics in contracts, along with triggers for model drift, output anomalies, and security incidents [4][5]. Set response levels for threshold breaches, from rate limiting and output restrictions to full system suspension [4].
